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Abstract
Fibromyalgia is a chronic illness involving widespread pain, and many related symptoms such as fatigue, mood
disorders, headache, and sleep disturbance. This condition has been traditionally difficult for health care
providers to treat with medications. Increasingly, treatment programs for individuals with Fibromyalgia have
included psychological therapies such as Cognitive Behavioral Therapy (CBT). CBT has shown preliminary
evidence to support its use in Fibromyalgia; however, there is a limited understanding of CBT in this
population. This meta-analysis examined all treatment studies, which included at least one group of patients
receiving CBT. Functional Status, Pain Symptoms, Depression, Anxiety and Psychological distress were used
as separate outcome variables to examine the effects of CBT. A literature review was conducted using Medline,
PsycINFO, and the Cochrane Central Register of Controlled Trials. Of the 2000 studies that were found, 29
research studies met criteria for inclusion in the study. This resulted in 1220 participants and 167 effect sizes
that could be examined. Effect sizes were corrected using Hedge’s correction for small sample bias aggregated
at the study level and the dependent variable level (function, pain, depression, anxiety and psychological
distress). All dependent variables in this analysis were significant and at least a medium effect size: Function
d=0.65 (95%CI 0.30 – 0.99), Pain Symptoms d=0.85 (95%CI 0.53 – 1.17), Depression d=0.69 (95%CI 0.34 –
1.04), Anxiety d=0.66 (95%CI 0.22 – 1.10), Psychological Distress d=0.76 (95%CI 0.37 – 1.14). Factors that
increased effect sizes across outcomes were the number of sessions and the use of a multidisciplinary therapy.
In summary, the evidence supporting the use of CBT to treat individuals with Fibromyalgia to improve
functioning, decrease pain, depression symptoms, anxiety symptoms and psychological distress is strong.
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ABSTRACT 
Fibromyalgia is a chronic illness involving widespread pain, and many related 
symptoms such as fatigue, mood disorders, headache, and sleep disturbance.  This 
condition has been traditionally difficult for health care providers to treat with 
medications.  Increasingly, treatment programs for individuals with Fibromyalgia have 
included psychological therapies such as Cognitive Behavioral Therapy (CBT).  CBT has 
shown preliminary evidence to support its use in Fibromyalgia; however, there is a 
limited understanding of CBT in this population.  This meta-analysis examined all 
treatment studies, which included at least one group of patients receiving CBT.  
Functional Status, Pain Symptoms, Depression, Anxiety and Psychological distress were 
used as separate outcome variables to examine the effects of CBT.  A literature review 
was conducted using Medline, PsycINFO, and the Cochrane Central Register of 
Controlled Trials.  Of the 2000 studies that were found, 29 research studies met criteria 
for inclusion in the study.  This resulted in 1220 participants and 167 effect sizes that 
could be examined.  Effect sizes were corrected using Hedge’s correction for small 
sample bias aggregated at the study level and the dependent variable level (function, pain, 
depression, anxiety and psychological distress).  All dependent variables in this analysis 
were significant and at least a medium effect size: Function d=0.65 (95%CI 0.30 – 0.99), 
Pain Symptoms d=0.85 (95%CI 0.53 – 1.17), Depression d=0.69 (95%CI 0.34 – 1.04), 
Anxiety d=0.66 (95%CI 0.22 – 1.10), Psychological Distress d=0.76 (95%CI 0.37 – 
1.14).  Factors that increased effect sizes across outcomes were the number of sessions 
and the use of a multidisciplinary therapy.  In summary, the evidence supporting the use 
of CBT to treat individuals with Fibromyalgia to improve functioning, decrease pain, 
depression symptoms, anxiety symptoms and psychological distress is strong. 
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INTRODUCTION 
Statement of the problem 
 Fibromyalgia is a syndrome that involves chronic widespread pain (Wolfe et al., 
1990). In addition, individuals with this syndrome experience a number of other 
symptoms such as sleep disturbance, fatigue, irritable bowel syndrome, headache and 
mood disorders (Wolfe, Ross, Anderson, Russell, & Hebert, 1995).  Individuals with 
fibromyalgia must learn to cope with a variety of symptoms and often require significant 
lifestyle changes (Sarzi-Puttini, Buskila, Carrabba, Doria, & Atzeni, 2008). It is highly 
stressful because its etiology is not yet known, and the course of the illness is 
unpredictable.  A further challenge for individuals with this syndrome is due to the 
limited effectiveness of standard treatments.  Multiple treatment options are available to 
individuals with fibromyalgia.  Available interventions include psychopharmacological 
treatments, physical treatments, complementary alternative medical treatments, and 
psychosocial treatments.  Results from individual studies suggest the efficacy of these 
interventions is limited, both in terms of percentage of patients who improve and in terms 
of symptom reduction (Sarzi-Puttini et al., 2008). 
Definition of Fibromyalgia 
Prior to 1990, there was no generally accepted definition for the syndrome of 
fibromyalgia.  Gomus first described fibrotitis in the early 1800’s as a syndrome with 
widespread pain.  However, it was not until 1977 when Smythe and Moldofsky ignited an 
interest in fibrositis syndrome (Smythe & Moldofsky, 1977).   
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In 1990, Wolfe and other experts in this field developed the American College of 
Rheumatology (ACR) criteria for the classification of Fibromyalgia.  The definition is 
reproduced here (Wolfe et al., 1990): 
Figure 1.  ACR criteria for a diagnosis of Fibromyalgia 
1. History of widespread pain. 
 
Pain is considered widespread when all of the 
following are present: pain in the left side of the 
body, pain in the right side of the body, pain above 
the waist, and pain below the waist.  
In addition, axial skeletal pain (cervical spine or 
anterior chest or thoracic spine or low back) must 
be present.  In this definition, shoulder and buttock 
pain is considered as pain for each involved side.  
"Low back" pain is considered lower segment pain.   
2. Pain in 11 of 18 tender point   
    sites on digital palpation. 
 
Pain, on digital palpation, must be present in at 
least 11 of the following 18 sites:  
- Occiput: Bilateral, at the suboccipital muscle 
insertions. 
- Low cervical: bilateral, at the anterior aspects of 
the intertransverse spaces at C5-C7. 
- Trapezius: bilateral, at the midpoint of the upper 
border. 
- Supraspinatus: bilateral, at origins, above the 
scapula spine near the medial border. 
- Second rib: bilateral, at the second costochondral 
junctions, just lateral to the junctions on upper 
surfaces. 
- Lateral epicondyle: bilateral, 2 cm distal to the 
epicondyles. 
- Gluteal: bilateral, in upper outer quadrants of 
buttocks in anterior fold of muscle. 
- Greater trochanter: bilateral, posterior to the 
trochanteric prominence. 
- Knee: bilateral, at the medial fat pad proximal to 
the joint line. 
 
• Digital palpation should be performed with an approximate force of 4 kg. 
• For a tender point to be considered "positive" the subject must state that the 
palpation was painful.  "Tender” is not to be considered "painful."  
• For classification purposes, patients will be said to have fibromyalgia if both 
criteria are satisfied. 
• Widespread pain must have been present for at least 3 months.  The presence of a 
second clinical disorder does not exclude the diagnosis of fibromyalgia (p 171). 
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The authors reported that sleep disturbance, fatigue and stiffness are present in 75% 
of patients who meet criteria for fibromyalgia.  Other symptoms such as anxiety, 
headaches and irritable bowel are more common in patients with fibromyalgia than in the 
general population.  
Prevalence of Fibromyalgia 
The prevalence of fibromyalgia in the United States is estimated at 5.0 million, 
approximately 2% of the population (Lawrence et al., 2008).  This estimate is based on 
the only prevalence study conducted in the US in 1995 conducted in Wichita (Wolfe et 
al., 1995). Although no recent prevalence studies of fibromyalgia in the US have been 
published, a population survey of 3,395 randomly selected adults in Canada showed 100 
cases of fibromyalgia, yielding an overall age/sex-adjusted prevalence of 3.3% (White, 
Speechley, Harth, & Ostbye, 1999). These investigators found that women are at three 
times the likelihood of men for having been diagnosed with fibromyalgia.  Other 
demographic factors that increase the odds of having fibromyalgia include middle age, 
less education, lower household income, being divorced, and being disabled (White et al., 
1999). 
Mechanism of Fibromyalgia 
The chronic widespread pain associated with fibromyalgia may be accounted for 
by dysregulatory processes in the central nervous system (CNS) (Okifuji & Turk, 1999). 
According to the central modulation model, dysfunctional pain mechanisms in the CNS 
are caused by abnormality in the neuroendocrine system, and over time may result in 
problematic feedback from pain to the CNS pain modulation (Yunus, 1992).  Researchers 
have reported differences in cortisol levels, serotonin levels, somatomedin C levels and 
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non rapid eye movement sleep between fibromyalgia patients and controls (Okifuji & 
Turk, 1999). Furthermore, there may be an increased level of “hypervigilance” among 
fibromyalgia patients, which causes a lower pain threshold and perhaps a lower threshold 
for perceiving fatigue (Lautenbacher & Rollman, 1997).  
Recent neurobiological evidence has shed light on the neural pathways in pain 
processing that may be dysregulated in patients with fibromyalgia.  As described by 
Bennett and Nelson (2006), the sensitization of the central nervous system can occur in 
persistent nocioceptor activation, which accrues in dorsal-horn neurons.  This process can 
be modified through the inhibitory descending pathway, which originates in the 
brainstem (Staud & Spaeth, 2008).  This pathway is mediated by serotonin and 
norepinephrine.  The limbic system and the frontal cortex also mediate this pathway.  
Thus, it is hypothesized that drugs that inhibit the reuptake of both serotonin and 
norepinephrine may act by stimulating the descending inhibitory pain pathway (Staud, 
2002).  
Okifuji and Turk (1999) describe a diathesis stress model for fibromyalgia that 
contains the CNS dysregulation factors but incorporates psychosocial factors as well.  
They hypothesize a process of physical manifestations of stress and the long-term effects 
of stress that take place in the body.  A stressor (psychological or situational) activates 
the neuroendocrine and psychosocial reactions (such as increasing cortisol levels or 
negative affect), which are mediated by biological and psychosocial predispositions (such 
as genetic factors or prior learning history) and lead to symptoms (such as fatigue).  In an 
adaptive process, the individual self-corrects and modifies their environment (uses 
relaxation etc.).  This leads to a return to baseline levels.  It is hypothesized that for some 
 individuals the self-corrective process does 
blocked by dispositional factors (such as dysfunctional thoughts) or environmental 
factors (such as multiple significant stressors) or both
returned to baseline, and new baseline is
dysregulation of the system.
Figure 2.  Diathesis stress model of Fibromyalgia
For example, a woman finds out that her husband is leaving her (stressor)
cortisol levels rise; she worries about her future, and 
sleeping and fatigue.  In and adaptive process
this helps her sleep, and reduces her anxiety and sadness
schedule and feel rested.  
reactivity to stressors.  In 
 
not occur.  Instead, the adaptive process is 
.  Thus, the individual is not 
 established which further reinforces 
  
 
feels sad.  This leads to difficulty 
, the woman may seek support from friends; 
.  She can resume her sleep 
Thus she can retain her baseline level of predisposition for 
a maladaptive process, the woman may think, “No one will 
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.  Her 
 ever love me, I’m unlovable,” and/or she may engage in a highly stressful court battle 
over her half of the assets
cortisol levels, negative emotions and disrupted sleep patterns
baseline predisposition for reactivity to stressors.
Figure 3.  Diathesis stress model of Fibromyalgia (with example)
These models are not mutually exclusive; they de
characterized by maladaptive information processing.
There is no known cure for fibromyalgia; however, there are multiple treatment 
options.  Among them are pharmacological, physical, psychological and other treatments. 
 
 
 
.  She continues to experience stress; she maintains high 
.  Thus she changes her 
 
 
fine fibromyalgia as a disorder 
 
Treatments for Fibromyalgia 
9
 
 
  
10 
Pharmacological treatments for fibromyalgia  
The main pharmacological intervention that has been investigated for 
fibromyalgia is antidepressants.  Two medications have recently been approved by the 
US FDA for the pharmacological treatment of fibromyalgia (Lyseng-Williamson & 
Siddiqui, 2008).  These are an anticonvulsant (pregabalin) and an antidepressant 
(duloxetine).  Both have been found to result in decreases in pain, anxiety and depressive 
symptoms in women with fibromyalgia.  However, improvements from medications that 
decrease pain in individuals with fibromyalgia are seen independently from changes in 
depression and anxiety.  Simple analgesics such as tramadol can also be considered in the 
treatment of fibromyalgia (Carville et al., 2008).  Other pharmacological therapies that 
have been evaluated include nonsteroidal anti-inflammatories, analgesics, sedatives and 
anxiolytics, and corticosteroids (Forseth & Gran, 2002). These therapies have 
demonstrated either minimally positive effects, no effects or negative effects with 
patients diagnosed with fibromyalgia. 
Physical treatments for fibromyalgia  
Physical exercise is thought be beneficial to patients with fibromyalgia and is 
directed at altering pain, fatigue, deconditioning, muscle weakness, and sleep disturbance 
(Forseth & Gran, 2002). Long-term participation in an exercise program has been 
associated with positive long-term outcomes in fibromyalgia (Wigers, Stiles, & Vogel, 
1996).  
Cognitive behavioral therapy for fibromyalgia  
On the basis of principles originally described by Turk and colleagues (Turk, 
Meichenbaum, & Genest, 1983), CBT has been used in the management of chronic pain 
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conditions for more than two decades. The theoretical assumption underlying CBT is that 
thoughts, emotions and behaviors are interrelated.  Following from this assumption, a 
change in one of these areas will produce change in the other two.  Patients often present 
to therapy with emotion as their targeted change area.  CBT typically focuses on patients’ 
thoughts and behaviors as the mechanisms for achieving the desired change.  Patients 
learn to identify, evaluate, and challenge unhelpful thoughts using cognitive and 
behavioral experiments.  Core beliefs influence assumptions and trigger automatic 
thoughts.  In addition, behaviors are thought to be maintained by the antecedents that 
precede them and consequences that follow them.  The goal of CBT is to help clients 
decrease the probability that the problem behavior will occur while increasing the 
likelihood of an adaptive behavior.  Specifically, the goals are (1) to continue the critical 
examination of problems, (2) to ensure that patients can execute effective coping skills in 
a given situation, (3) to ensure that patients learn to monitor their thoughts and behaviors 
during daily activities, and (4) to gradually establish new ways of thinking and 
responding.  
CBT has been applied to clients with chronic pain (Turk et al., 1983). The CBT 
model supports the view that affective, behavioral, cognitive and sensory or physical 
aspects.  These are important factors for understanding the patient’s experience of pain, 
and emphasize the influence of the individual’s beliefs on the pain experience.  CBT 
attempts to use cognitive restructuring and behavioral experiments to reduce the 
inappropriate emotional responses to pain and other symptoms.  This process of reducing 
maladaptive responses to pain sensations over time and repetition gradually results in 
reduced activation in neural circuitry for pain.  The goals of CBT for chronic pain 
  
12 
typically include increasing a patients’ sense of control over their pain and decreasing 
maladaptive thought patterns and associated behavioral improvements. 
Evidence for treatments in fibromyalgia 
 In 1999, a meta-analysis was conducted to evaluate the effectiveness of 
pharmacological and non-pharmacological treatments for fibromyalgia (Rossy et al., 
1999).  Forty-nine studies of varying methodological quality were included and four 
outcome variables were included (physical status, self-report of fibromyalgia symptoms, 
psychological status, and daily functioning).  Pharmacological treatments demonstrated 
improvements in physical status and self-report of symptoms; whereas, non-
pharmacological treatments were overall effective in reducing physical status, self-report 
of symptoms, psychological status, and daily functioning.  When treatments were 
compared, non-pharmacological treatments were more effective at improving self-report 
of symptoms and functional status.  
Evidence for pharmacological treatments  
In a meta-analytic review of 13 randomized, placebo controlled trials suggested 
that antidepressants improve the symptoms of fibromyalgia (O'Malley et al., 2000). 
Patients treated with antidepressants were more than four times as likely to improve.  
There appear to be mild improvements for fibromyalgia symptoms of fatigue, number of 
trigger points, and overall well-being; moderate improvement was found for sleep, and 
pain severity.  The researcher reported that there was inadequate evidence to determine if 
a relationship exists between pharmacological treatment for fibromyalgia and 
improvement in depression symptoms. 
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Arnold, Keck, and Welge conducted a meta-analysis of the effects of tricyclic 
antidepressant on the symptoms of fibromyalgia (Arnold, Keck, & Welge, 2000). They 
found that tricyclics had a moderate effect on these symptoms.  In particular, these 
medications were found to have the highest effect on sleep symptoms.  Moderate effects 
were also found for pain, functioning and for tender points.  This study did not examine 
the effects of antidepressants on symptoms of anxiety and depression.  
A recent meta-analysis of antidepressant effects on fibromyalgia was conducted 
(Hauser, Bernardy, Uceyler, & Sommer, 2009). Researchers examined randomized 
controlled trials of tricyclic antidepressants (TCAs), selective serotonin reuptake 
inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), and 
monoamine oxidase inhibitors (MAOIs) found that there was evidence for an association 
of antidepressants with moderate reduction in pain, and small reductions in fatigue, 
depressed mood, and sleep disturbances.  Effect sizes for pain reduction were large for 
TCAs medium for MAOIs and small for SSRIs and SNRIs.  
Tramadol is a centrally acting analgesic medication.  It has a dual effect of being a 
weak opioid and it inhibits the reuptake of serotonin and noradrenaline.  Recent 
randomized controlled trials of tramadol have shown decreases in pain in patients with 
fibromyalgia (Bennett, Kamin, Karim, & Rosenthal, 2003; Russell et al., 2000).  The use 
of analgesics in patients with fibromyalgia could be used with some caution due to the 
possibility of opiate withdrawal effects and tolerance (Carville et al., 2008). 
 
Evidence for physical treatments  
 A recent comprehensive review of literature on exercise therapy for fibromyalgia 
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was in support of physical exercise as a treatment for fitness and improvement in 
symptoms (Jones, Adams, Winters-Stone, & Burckhardt, 2006). The researchers 
reviewed forty-six studies that examined a standardized exercise program in patients with 
fibromyalgia.  They examined studies that looked at visual analogue scales of symptoms, 
health and impact questionnaires.  Subjects achieved symptom relief, particularly 
decreased pain and fatigue as well as improved sleep and mood, with low to moderate 
intensity exercise of any type.  In general, the greatest effect and lowest drop out rates 
occurred in exercise programs that were of lower intensity than those of higher intensity. 
A recent meta-analysis was conducted to examine the effects of multicomponent 
treatment in fibromyalgia (Hauser, Bernardy, Arnold, Offenbacher, & Schiltenwolf, 
2009). Multicomponent therapies include at least one exercise therapy and at least one 
psychological or educational therapy.  Nine studies that met these criteria were included 
in the analysis.  Researchers found that interventions that combined physical and 
psychological interventions were effective in significantly reducing pain, depression and 
increases quality of life.  The most dramatic effects of these interventions were for 
depressed mood and fatigue.  Pain and physical fitness effect sizes were small to 
moderate, but significant. 
Evidence examining CBT in Fibromyalgia  
Neilson and his colleagues conducted the first investigation of using CBT in 
patients with fibromyalgia (Nielson, Walker, & McCain, 1992). They administered a 
comprehensive cognitive behavioral treatment that included relaxation, cognitive 
techniques, aerobic exercise, pacing strategies, family education, a return to home and 
community activities and medication management.  Patients were assessed both pre and 
  
15 
post intervention times and improvement was seen in the areas of pain severity, 
emotional distress, anxiety, depression, and life interference (functional status).  
However, improvement was not statistically significant for patients on overall activity 
level.  Two years later, a follow-up study was done to investigate the long-term benefits 
of this type of treatment in patients with fibromyalgia.  Control over pain, worry and 
observed pain behavior continued to show a significant decrease from baseline levels.  
Vlaeyen and colleagues examined a cognitive educational treatment for 
fibromyalgia using a randomized control trial (Vlaeyen et al., 1996). In their sample, the 
patients had significant disability.  The majority of patients was unemployed, fearful, and 
had experienced pain symptoms for an average of ten years.  The majority of patients did 
not experience significant treatment reductions in symptoms as a result of the treatments.  
The cognitive educational group showed significant improvements in pain coping and 
pain control; however, they did not show statistically significant improvements in pain 
behavior, pain intensity, activity levels, depression or anxiety.  
Patients with fibromyalgia were randomly assigned to either an aerobic exercise 
program, a stress management program, or treatment as usual (Wigers et al., 1996). 
Patients in both the aerobic exercise group and the stress management group showed a 
statistically significant reduction in their dolorimeter score, which assesses the tender 
points.  The majority of clients did not experience significant symptoms (pain, 
depression, and functional activities) reduction at the end of the treatment period.  The 
aerobic exercise interventions lead to a reduction of symptoms; however, few patients 
continued the treatment at follow up.  At follow up, the majority of patients had 
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continued the stress management daily or twice weekly.  In particular, 69% continued 
with relaxation strategies in spite of “no effects.”  
Behavioral and education/control interventions in a group format were evaluated 
in the treatment of 72 men and women with fibromyalgia (Nicassio et al., 1997). Groups 
met for 90 minutes each week for 10 weeks.  The investigators found that there were 
improvements across time for both groups, but that there was no difference between 
groups in that.  Significant reductions in depression, self-reported pain behavior, 
observed pain behavior, and myalgia scores occurred.  However, changes in function and 
well-being did not occur over the course of the trial.  
Buckelew and her colleagues examined the effects of a therapy comparing 
biofeedback and relaxation to exercise and a combination of the two (Buckelew et al., 
1998).  All three groups showed an increase in self-efficacy for function.  The relaxation 
and biofeedback group showed short-term improvements in pain scores.  Furthermore, 
depression did not change in the short-term but showed significant improvement in the 
two-year follow up period.  The exercise and combination groups obtained modest 
improvements on the physical activity score.  The investigators also found support for the 
hypothesis that treatment may prevent the development of increased tender spots in 
untreated individuals.  In the long term, only the combination group continued to show an 
increase in self-efficacy for function. 
Another group compared EMG biofeedback to sham-biofeedback as a treatment 
for individuals with fibromyalgia (Babu, Mathew, Danda, & Prakash, 2007). Patients 
were randomized to receive 6 days of 45-minute sessions of either biofeedback or sham 
biofeedback, which consisted of an alteration of the visual feedback provided to the 
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client, irrespective of their muscle activity.  The authors found that there were significant 
decreases in functional status, pain, and number of tender points in the group that 
received biofeedback.  This study did not examine depression or anxiety. 
These researchers compared standard medication treatment including 
pharmacological interventions and suggestions for exercise with and without the addition 
of a brief intensive cognitive behavioral intervention (Williams et al., 2002).  This 
intervention was specifically targeted at increasing physical function.  Results indicate 
that physical function improved.  Depression and anxiety measures were not reported.  
Pain was unaffected by the addition of the intervention.  This is consistent with the pain 
literature in that pain is not consistently associated with physical function. 
Patients with fibromyalgia were randomized to receive operant behavioral 
treatment or physical therapy (Thieme, Gromnica-Ihle, & Flor, 2003). Significant 
improvements were found in the operant group on dependent measures of pain intensity, 
interference, affective distress (depression and anxiety), self-efficacy, spousal response to 
pain, medication intake and pain behaviors.  These improvements were demonstrated in 
spite of concurrent reduction in medication intake.  No improvements were found for 
total activities.  The physical therapy and medication management comparison group 
deteriorated in almost all variables measured. 
Fifty-six fibromyalgia patients were randomly assigned to participate in either a 
cognitive behavioral or physical exercise based therapy (Redondo et al., 2004).  Patients 
in the exercise group demonstrated improvement in physical activity, but not in 
functional status (common finding).  Patients in the CBT groups demonstrated 
improvement in functional status as well, but not in terms of depression, anxiety or self-
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efficacy.  CBT increased the use of strategies to manage pain such as relaxation.  Neither 
group reported significant decreases in pain. 
CBT was examined in a sample of adolescents with fibromyalgia (Redondo et al., 
2004).  The patients were randomly assigned to either an 8-week CBT group or 8 weeks 
of self-monitoring.  At week 8, both groups showed a decrease in depression and 
functional disability.  Patients who received CBT showed significant ability to cope with 
pain and a trend towards decreased pain intensity; however, there was no objective 
decrease in pain for either group.  Those in the self-monitoring group followed by the 
CBT group seemed to receive the most benefit. 
These investigators examined the differential effects of psychopharmacological 
(amitryptiline or cyclobenzapine) interventions, CBT, and CBT and pharmacological 
interventions combined on patients with fibromyalgia (Garcia, Simon, Duran, Canceller, 
& Aneiros, 2006).  CBT decreased fibromyalgia symptoms in both post treatment and 
follow up time periods.  Interestingly, the CBT and psychopharmacological approached 
did not show similarly significant improvements in symptoms.  Number of tender points 
trended towards improvement in the CBT group.  Depression and anxiety were measured 
initially but were not followed up after treatment because a physician conducted blinded 
follow up assessments of FIQ and number of tender points.  
Hammond and Freeman (2006) compared a patient education program combined 
with exercise to a relaxation group.  Short-term benefits from the education and exercise 
group are evident; however, long-term benefits were not sustained (Hammond & 
Freeman, 2006).  Doctors’ visits were reduced in both groups these changes were 
maintained over time.  No changes in depression and anxiety were reported.  
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Furthermore, reports of pain did not significantly improve in either group.  The authors 
identified additional treatment components that may have improved the effectiveness of 
the treatments.  They recommended motivational interviewing, home-based treatment, 
and more homogeneous groups of patients. 
A quasi-experimental study was conducted to examine the effectiveness of group 
therapy specifically targeted towards promoting adaptive active coping skills on a 
cognitive, behavioral, and emotional level in patients with fibromyalgia (Anderson & 
Winkler, 2007). The investigators found significant improvements in depression, pain, 
and fatigue.  Overall, the treatment group experienced an improvement in functioning.  
Anxiety was not monitored in this study. 
Mindfulness-based therapies are a recent development in the treatment of chronic 
pain (Kabat-Zinn, Lipworth, & Burney, 1985). Researchers have attempted to compare 
the use of a mindfulness based stress reduction (MBSR) treatment program to standard 
treatment for individuals with fibromyalgia (Sephton et al., 2007).  The MBSR group had 
significantly reduced depressive symptoms.  This study did not report changes in anxiety, 
physical functioning or pain.  
One hundred and twenty five patients with fibromyalgia were randomly assigned 
to participate in operant behavioral and cognitive behavioral therapies (Thieme, Flor, & 
Turk, 2006).  The cognitive group focused on changing maladaptive cognitions 
associated with pain and providing coping strategies.  The operant group focused on 
changing observable pain behaviors and utilized punishment and reinforcement.  Both 
groups demonstrated significant improvement in a one-year follow up period as 
compared to an attention control group.  Furthermore the attention control group which 
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consisted of a discussion of symptoms and problems caused by fibromyalgia resulted in a 
50% drop out rate and an increase in symptoms.  In particular, improvements were seen 
in functional status, and pain intensity.  Affective distress (which captures depression and 
anxiety) did not show significant reductions for either group. 
As a follow up study to the study by Thieme, Flor and Turk (2006), this group 
considered specific patient characteristics that responded well to treatment in the trial.  In 
particular, the authors conducted a multiple regression analysis to determine which 
patient characteristics would predict improvement in pain intensity and physical 
impairment (Thieme, Turk, & Flor, 2007). The authors found that patients responded to 
both treatments in terms of decreasing physical impairment if they had a higher initial 
physical impairment, lower initial affective distress, higher initial pain behaviors and 
reduced solicitous spousal behavior.  The authors found that patients responded to both 
treatments in terms of decreasing pain intensity if they had lower initial physical 
impairment.  Of note, psychological variables did not predict reductions in pain.   
Two literature reviews regarding the use of CBT for patients with patients with 
fibromyalgia have been published (Bennett & Nelson, 2006; van Koulil et al., 2007).  
Bennett and Nelson (2006) found that CBT does not provide sustained pain relief to 
patients with fibromyalgia.  The primary function of CBT for patients with fibromyalgia 
is related to improvements in areas other than pain.  Specifically, these reviewers 
concluded that we should look to CBT to provide improvements in self-efficacy, 
dysfunctional thought patterns and physical functioning.  
The second review was conducted to examine the effects of CBT, exercise 
programs or the combination of the two (van Koulil et al., 2007).  The authors reported 
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that multimethod treatments were more effective than specific CBT components 
provided.  However, effects from both treatments tended to disappear in the long term.  
They further suggested that outcomes might be improved if there were opportunities to 
specifically target specific groups of patients within the group of fibromyalgia patients. 
One potential reason for some of the inefficiencies found in treatment programs 
could be the heterogeneity of patients in the groups.  In their article of 1996, Turk and his 
colleagues investigated a group of patients with fibromyalgia using structural equation 
modeling to determine if patients could be separated into subgroups based on 
psychosocial and behavioral responses to pain (Turk, Okifuji, Sinclair, & Starz, 1996). 
They found that there were three groups of patients that could be grouped together.  The 
dysfunctional group is characterized by poor coping and high level of pain, the 
interpersonally distressed group is characterized by interpersonal difficulties, and low 
pretreatment levels of affective distress and disability characterize the adaptive coper 
group.  One study examined how these groups respond to standard interdisciplinary 
treatment for fibromyalgia (Turk, Okifuji, Sinclair, & Starz, 1998). The dysfunctional 
group experienced statistically significant reductions in pain, affective distress, perceived 
disability, and perceived interference of pain.  The interpersonally distressed group was 
not responsive to this treatment.  The adaptive coper group experienced significant 
reductions in pain, but did not show reductions in their already low levels of functional 
disability an affective distress.  The authors emphasized using customized treatment 
programs based on the patients’ psychosocial and behavioral responses to pain and 
hypothesized that this will lead to improved outcomes in treatments. 
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  A group of researchers from the Netherlands utilized a case study design to better 
understand the effects of customizing treatment for different groups of patients (van 
Koulil et al., 2008).  They differentiated between patients with fibromyalgia based on two 
patterns of psychosocial and behavioral responses to pain: the pain-avoidant pattern and 
the pain-persistence pattern.  The pain avoidant pattern is best characterized by a high 
level of pain avoidance behaviors, preoccupation with painful stimuli, pain related 
worrying, and fear of pain or movement.  The pain persistence pattern is characterized by 
a low level of pain avoidance behavior, activity in spite of pain, ignoring pain a physical 
limits, and non-acceptance and demanding cognitions about limitations.  The therapeutic 
approach that was useful with a patient who is characterized by a pain-avoidant pattern 
was aimed at diminishing fear of pain and increasing the level of daily activity.  The 
therapeutic approach that was useful with a patient who is characterized by a pain-
persistence pattern was aimed at changing pain-persistence cognitions and achieving a 
regulation of daily activities. 
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HYPOTHESES 
Studies examining the effects of CBT in patients with fibromyalgia will demonstrate 
effectiveness of the treatment for outcomes of pain, functioning, depression, anxiety and 
psychological distress.  
1. CBT will improve the symptoms of pain in individuals with fibromyalgia between 
pre- and post CBT treatment. 
2. CBT will improve the functioning in individuals with fibromyalgia between pre- 
and post CBT treatment. 
3. CBT will improve the symptoms of depression in individuals with fibromyalgia 
between pre- and post CBT treatment. 
4. CBT will improve the symptoms of anxiety in individuals with fibromyalgia 
between pre- and post CBT treatment. 
5. CBT will improve the symptoms of psychological distress in individuals with 
fibromyalgia between pre- and post CBT treatment. 
  
24 
METHOD 
Study retrieval 
 The electronic bibliographic databases screened included Medline (1950 through 
August 2009), PsycINFO (1950 through August 2009), and the Cochrane Central 
Register of Controlled Trials (1993 through August 2009).  Dates were chosen to be most 
inclusive of potential studies.  The keywords used in the initial inclusion were 
“fibromyalgia” and “fibromyalgia syndrome” in combination with “cognitive behavioral 
therapy,” “cognitive therapy,” and “behavior therapy.”  In addition, reference sections of 
original studies and review papers on cognitive behavioral therapy for fibromyalgia were 
screened manually by the author (SG).  Only studies in English were included.  Of the 
2000 studies that were found using this search, 205 of the abstracts were reviewed for the 
study based on their mention of fibromyalgia in their abstract.  Of the 205 abstracts, 155 
were determined to be ineligible for the study (See Figure 4), and 50 were included for 
more in-depth review by the author.  Of the 50 that were included for review, the author 
could not obtain 3 of the articles, 1 article was in French, 1 article was a duplicate and 21 
articles were determined to be ineligible for the study (See Figure 4).  Twenty-nine 
articles remained and were included in the study.  Of the 29 studies, 3 had two groups 
that could be examined in this study (CBT, and CBT and hypnosis, cognitive therapy and 
operant behavior therapy, and pain-avoidance treatment and pain-persistence treatment) 
this resulted in a total of 32 groups that were examined in the meta-analysis (Anderson & 
Winkler, 2007; Burckhardt, Clark, O'Reilly, & Bennett, 1997; Castel, Salvat, Sala, & 
Rull, 2009; Creamer, Singh, Hochberg, & Berman, 2000; Edinger, Wohlgemuth, Krystal, 
& Rice, 2005; Falcao et al., 2008; Fors & Gotestam, 2000; Garcia et al., 2006; 
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Goldenberg et al., 1994; Hammond & Freeman, 2006; Keel, Bodoky, Gerhard, & Muller, 
1998; Kroese et al., 2009; Lera et al., 2009; Lumley et al., 2008; Menzies & Kim, 2008; 
Menzies, Taylor, & Bourguignon, 2006; Nicassio et al., 1997; Nielson et al., 1992; 
Sephton et al., 2007; Shapiro, Anderson, & Danoff-Burg, 2005; Singh, Berman, 
Hadhazy, & Creamer, 1998; Suman et al., 2009; Thieme et al., 2006; Thieme et al., 2003; 
van Koulil et al., 2010; Vazquez-Rivera et al., 2009; Vlaeyen et al., 1996; Wigers et al., 
1996; Williams et al., 2002).  
 
Figure 4.  Flow diagram of literature review and application of inclusion and exclusion criteria. 
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Inclusion and Exclusion Criteria 
 To be included in the analysis, studies were required to meet the following criteria: 
1) the study included at least one group receiving cognitive therapy or behavioral therapy 
or some combination, 2) the diagnosis of fibromyalgia has to be based on recognized 
criteria (e.g., Wolfe et al., 1990 criteria, ACR criteria), 3) the study had to report pre- and 
post- measures for their treatment group, 4) the study had symptom specific outcomes of 
the keys symptoms of fibromyalgia, such as pain, fatigue, depressive symptoms, and 
health related quality of life, and/or relevant pain-related psychological domains, and/or 
objective tests of physical fitness, 5) the study was published in full paper form, and 6) 
data was suitable for meta-analysis (e.g., appropriate numerical information needed to 
calculate effect size such as number of participants in the treatment group, means and 
standard deviations pre- and post-treatment).  In three studies estimations were used to 
compute effect sizes.  One study was excluded due to incomplete data (i.e., only baseline 
scores and standard deviations and t-scores looking at the difference in scores between 
treatment successes and treatment failures, not post treatment scores were available) 
presented in the article; the author (SG) attempted to contact these authors, but was 
unable to make contact.  Studies were excluded from the analysis on the basis of the 
following criteria: 1) The use of ONLY psychoeducation for treatment, 2) the use of 
ONLY relaxation for treatment, 3) the use of a non-adult (under age 18) sample, 4) 
studies examining follow up, intent to treat, or adherence only, i.e., no pre-post data for 
analysis (as above). 
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Coding Manual 
Codes were both developed for the present study and taken from the example in 
the book Practical Meta-analysis (Lipsey & Wilson, 2001). Appendix A presents details 
of codes.  Effect sizes were computed independently of other coding to avoid bias the 
might result from knowing outcomes.  A description of the variables coded in the study 
follows (Please see appendix A for full Coding Manual used). 
Sample descriptors –Four sample descriptors were used: (a) mean age of the 
sample, (b) predominant sex of sample, (c) average duration of fibromyalgia symptoms in 
the sample, (d) whether or not medications were being used by the sample. 
Research design descriptors – Four research design descriptors were used: (a) 
type of treatment (b) scientific integrity of the research design, (c) initial treatment group 
size, (d) follow-up treatment size, and (e) attrition.  
Nature of treatment descriptors – Three of treatment descriptors were used: (a) 
CBT components of the treatment (each component of CBT was graded separately and 
indicated if present vs. not present), (b) duration/length of the treatment, and (c) time 
until follow up. 
Dependent variables – Four dependent variables were used: (a) functional ability, 
(b) pain, (c) depression, and (d) anxiety.  The type of scale used was also coded for 
analysis.  Following data collection, one additional dependent variable was added called 
(e) level of distress, and was distinguished from measures that looked exclusively at 
depression and negative mood.  Each measure used in the studies was coded as one of 
these five dependent variables, and codes are provided for those in the coding manual.  
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Effect sizes – Eight effect size variables were used: (a) page number, (b) treatment 
group size, (c) mean pre-intervention, (d) standard deviation pre-intervention, (e) mean 
post-intervention, (f) standard deviation post-intervention, (g) effect size, (h) raw 
difference. 
Statistical Analysis 
Reliability Analysis 
Interrater reliability 
A reliability analysis was conducted in which two graduate students coded six 
variables within all studies independently.  Four continuous variables, pre-treatment 
means and standard deviations, post-treatment means and standard deviations of all 167 
effect sizes and two categorical variable, type of dependent variable (function, pain, 
depression, and anxiety) and specific for the dependent variable were selected for the 
reliability study. 
A Pearson correlation was computed for the continuous variables; the pre-
treatment mean (r= .95), the pre-treatment standard deviation (r= .99), the post-treatment 
mean (r= .96), the post-treatment standard deviation (r= .99).  The results indicated a 
high level of agreement between raters with respect to the pre and post treatment means 
and standard deviations.  A coefficient kappa was computed for both of the categorical 
variables; type of dependent variable (K = .97), and specific type of dependent variable 
(K= .85).  According to Fleiss, both values represent excellent agreement beyond chance 
(Fleiss, 1981). The disagreement between coders was resolved by the author by 
examining each disagreement and comparing it to the original article.  No changes were 
made to the coding manual as a result of this analysis. 
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Intra-rater reliability 
A reliability analysis was conducted by the author on 10% on the studies for all of 
the study variables, which was done to ensure consistency and quality of coding by the 
author.  The studies were randomly selected.  All variables in the study were examined.  
Sixteen continuous variables were examined using Pearson correlations (age, sex, 
duration of illness, N at baseline, N at follow up, weeks of treatment (weeks), number of 
sessions, length of sessions (minutes), time to first follow up(months), time to second 
follow up (months), size of the treatment group, pre-treatment means and standard 
deviations, post-treatment means and standard deviations) and 7 categorical variables 
were examined using coefficient kappa (diagnostic criteria used, medications, type of 
therapy delivery, scientific quality and type of dependent variable (function, pain, 
depression, anxiety, and psychological distress), specific type of the dependent variable 
and raw score difference (improvement, decline, no change)).  Results of the intra-rater 
reliability study are presented in Table 1.  Overall, these results indicated a moderate to 
high level of intra-rater reliability.  All discrepancies were reviewed by the author, and 
compared to the original article for confirmation. 
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Table 1.  Intra-rater reliability with 10% of the studies included in the analysis (n =11) 
Continuous Variables r Categorical Variables K 
Age 0.98 Diagnostic Criteria  0.74 
Sex 0.97 Medications 0.72 
Duration of Illness 0.96 Type of Therapy  1.00 
Baseline (n) 
1.00 Scientific Quality 0.84 
Follow-up (n) 1.00 Dependent Variable  0.96 
Weeks of Treatment (weeks) 1.00 Dependent Variable (Specific) 0.91 
Number of Sessions 1.00 Score Difference (Raw) 0.90 
Length of Sessions (minutes) 1.00   
Time to first follow-up  (months) 1.00   
Time to Second Follow-up 
(months) 
1.00 
  
Treatment Group (Size) 1.00   
Pre-treatment (mean) 1.00   
Pre-treatment (SD) 1.00   
Post-treatment (mean)  1.00   
Post-treatment (SD) 0.99   
 
 
Effect Size Calculation  
Effect sizes were calculated for this meta-analysis using the standardized mean 
difference statistic.  When possible, effect sizes will be calculated directly using this 
formula: 
 d = Xpost -  Xpre 
  sp 
where Xpre  is the mean score of the treatment group prior to receiving treatment and Xpost 
is the mean of the score of the treatment group following treatment, and sp is the pooled 
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standard deviations.  When this information was not reported I estimated d using an 
effect size calculator (Shadish, Robinson, & Lu, 1999). 
Statistical analysis 
First, the effect sizes were corrected using Hedge’s correction for small sample 
bias in the standardized mean difference effect size (Hedges, 1981). The effect sizes were 
then aggregated at the study level and the dependent variable level (function, pain, 
depression and anxiety) and descriptive statistic analyses including the quartiles, means, 
standard deviations and the range were performed (for both aggregated data and non-
aggregated data).  Using Hoaglin’s method to determine upper bound and lower bound 
outliers (Hoaglin, Iglewicz, & Tukey, 1986). Thirteen outliers were found.  After careful 
consideration of each outlier, all outliers were kept for the analysis; a detailed analysis of 
all outliers is noted below for each dependent variable.  Combined effect sizes and 
associated statistics were computed such as the weighted mean effect size, the conditional 
variance of effect size, and the confidence intervals around the effect sizes.  Homogeneity 
analyses were conducted on the effect sizes for each dependent variable level.  In light of 
the inclusion criteria identified for this study including a wide range of eligible studies, it 
was pre-determined that the study would be carried out using the random effects model, 
due to the ability of this model to adjust for both subject level variance, but also study 
level variance.  
The meta-analysis analog to the analysis of variance was conducted to determine 
how much variance in effect sizes is due to categorical variables that were thought to 
impact the average effect size.  Level of scientific quality and type of CBT treatment 
(Individual, group, multidisciplinary) were used because they were both thought to have 
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impacted the average effect size.  Furthermore, the weighted regression analysis was 
performed to determine how much of the variance in effect sizes is due to continuous 
variables.  The continuous variables investigated here were the length of CBT sessions, 
the duration of treatment, the number of CBT treatments used, and attrition.  
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RESULTS 
Descriptive Results 
Twenty-nine studies were included in the meta-analysis for review, the total 
sample size across all the studies reviewed was n =1220.  As previously indicated, three 
studies had two groups that were examined, this resulted in 32 groups.  The average age 
of participant across groups was 45.6 (SD 8.5), the average percentage of female gender 
was 95.6%, and the average duration of fibromyalgia symptoms was 7.95 years.  On 
average CBT treatment took and average of 9.8 weeks, 13.1 sessions, and sessions were 
121.9 minutes in length.  Each group included some component of CBT, and Table 2 
indicates the percentage of studies that contained each component of CBT. 
The effect sizes were first examined to determine if the data contained any 
outliers.  Effect sizes after aggregation for all studies had a lower bound for outliers of     
–0.77, and an upper bound of 1.96.  Thirteen effect sizes fell outside this range from 
d=2.08 to d=5.52; they were included in subsequent analyses because upon examination, 
they were confirmed to meet inclusion criteria for the study and no errors were found.  Of 
the 169 effect sizes computed, after aggregation there were twenty-two study-level effect 
sizes for functional status, thirty-one study-level effect sizes for pain, seventeen study-
level effect sizes for depression, fourteen study-level effect sizes for anxiety and twelve 
study-level effect sizes for psychological distress.  Next, the distribution of effect sizes 
for the studies was analyzed by the dependent measure.  
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Table 2.  Description of Cognitive Behavioral Therapy components (n = 32) 
CBT Components Percent of groups containing the specific component  
Relaxation Training 87.5 
Psychoeducation 81.3 
Homework 78.1 
Chronic Pain Self-management 78.1 
Self-monitoring 68.8 
Stress Management 65.6 
Cognitive Restructuring 59.4 
Exercise 37.5 
Exposure/Behavior Modification 28.1 
Pleasant Activity Scheduling 28.1 
Problem Solving 25.0 
Support Person Involvement 25.0 
Assertiveness Training and/or 
Social Skills Training 
25.0 
Biofeedback 12.5 
Sleep Hygiene 12.5 
CBT = Cognitive Behavioral Therapy 
 
Functional status  
After aggregation there were twenty-two effect sizes for the dependent measure 
functional status which ranged from d = 0.00 to d = 3.95 with a mean of 0.64.  Effect 
sizes for functional status had a lower bound for outliers of –0.57, and an upper bound of 
1.46.  One effect size fell outside this range, d =3.95.  A homogeneity analysis was 
conducted and the results indicated a heterogeneous distribution (χ2 (22) = 241.05, p < 
0.001).  The null hypothesis for homogeneity was rejected suggesting that it cannot be 
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assumed that the data contains only subject level variability, but also some study level 
variability, and indicating the use of a random effects model.  
The mean effect size of the random effects model was d =0.65 (SE = 0.17).  Also, 
the confidence intervals were wider under the random effects model because the 
between-study variability is added to sampling error variability and thus increases the 
uncertainty associated with the estimate of the population mean.  The mean effect size 
was found to be significantly different from zero.  
The mean effect size for the sample of studies under the random effects model 
was 0.65 (SE = 0.18) and was statistically significant (z =3.68, p = 0.0002).  The 95% 
confidence interval around the mean effect size (0.30 < µ < 0.99) did not include zero and 
reveals the relevant precision of the estimate of the mean effect size.  The variance 
component for the random effects analysis is 0.63 indicating that approximately 63% of 
the variance is not accounted for by sampling error.  
Several analyses were conducted to test the ability of several categorical and 
continuous variables to explain the excess effect size variability.  Results of these 
analyses are summarized in Tables 3 and 4.  For functional status, scientific quality, type 
of CBT treatment, number of CBT components, number of weeks, and attrition rates did 
not significantly contribute to the variability in functional status.  Number of sessions did 
account for 29% of the variance (R2=0.30, p = 0.003) in effect sizes for functional status. 
Pain  
After aggregation there were thirty-one effect sizes for the dependent measure 
pain which ranged from d = 0.10 to d = 4.5 with a mean of 0.85.  Effect sizes for pain had 
a lower bound for outliers of –0.43, and an upper bound of 1.74.  Two effect sizes fell 
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outside this range, d =2.75 and d =4.50.  A homogeneity analysis was conducted and the 
results indicated a heterogeneous distribution (χ2 (30) = 319.94, p < 0.001).  The null 
hypothesis for homogeneity was rejected suggesting that it cannot be assumed that the 
data contains only subject level variability, but also some study level variability, and 
indicating the use of a random effects model.  
The mean effect size for the sample of studies under the random effects model 
was 0.85 (SE = 0.16) and was statistically significant (z =5.18, p < 0.001).  The 95% 
confidence interval around the mean effect size (0.53 < µ < 1.17) did not include zero and 
reveals the relevant precision of the estimate of the mean effect size.  The variance 
component for the random effects analysis is 0.73 indicating that approximately 73% of 
the variance is not accounted for by sampling error.   
Several analyses were conducted to test the ability of several categorical and 
continuous variables to explain the excess effect size variability.  Results of these 
analyses are summarized in Tables 3 and 4.  For pain, scientific quality, number of CBT 
components, number of weeks, and attrition rates did not significantly contribute to the 
variability in pain.  Number of sessions did account for 29% of the variance (R2=.29, p = 
0.001) in effect sizes for pain.  For the random model the value of the variance 
component for type of CBT treatment was statistically significant, Q (2)=11.13, p = 
0.004.  Studies using individual CBT (n= 4) had a mean d = .60 (SE = 0.49) and a 95% 
confidence interval of -0.35 to 1.56, which was not significantly different from group 
CBT (n= 25) having a mean d = 0.67 (SE = 0.16) and a 95% confidence interval of 0.36 
to 0.98; however, multidisciplinary CBT treatment (n= 5) was significantly different from 
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both having a mean of d = 2.01 (SE = 0.38) and a 95% confidence interval of 1.27 to 
2.74.  
 
Depression  
After aggregation there were seventeen effect sizes for the dependent measure 
depression which ranged from d = -0.10 to d = 2.67 with a mean of 0.69.  Effect sizes for 
depression had a lower bound for outliers of –0.68, and an upper bound of 1.95.  One 
effect size fell outside this range, d =2.66.  A homogeneity analysis was conducted and 
the results indicated a heterogeneous distribution (χ2 (17) = 153.72, p <0.001).  The null 
hypothesis for homogeneity was rejected suggesting that it cannot be assumed that the 
data contains only subject level variability, but also some study level variability, and 
indicating the use of a random effects model.   
The mean effect size for the sample of studies under the random effects model 
was 0.69 (SE = 0.18) and was statistically significant (z =3.85, p = 0.0001).  The 95% 
confidence interval around the mean effect size (0.34 < µ < 1.04) did not include zero and 
reveals the relevant precision of the estimate of the mean effect size.  The variance 
component for the random effects analysis is 0.50 indicating that approximately 50% of 
the variance is not accounted for by sampling error.  
Several analyses were conducted to test the ability of several categorical and 
continuous variables to explain the excess effect size variability.  Results of these 
analyses are summarized in Tables 3 and 4.  For depression, scientific quality, number of 
CBT components, number of weeks, and attrition rates did not significantly contribute to 
the variability in depression.  Number of sessions did account for 21% of the variance 
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(R2=.21, p = 0.01) in effect sizes for depression.  For the random model the value of the 
variance component for type of CBT treatment was statistically significant Q (1) = 6.98, 
p = 0.04.  Studies using group CBT (n= 15) had a mean d  = 0.51 (SE = 0.15) and a 95% 
confidence interval of 0.22 to 0.81, which was significantly different from 
multidisciplinary CBT (n= 3) having a mean d = 1.46 (SE = 0.32) and 95% confidence 
interval of 0.82 to 2.09.  
Anxiety 
After aggregation there were fourteen effect sizes for the dependent measure 
anxiety which ranged from d = -0.12 to d = 2.99 with a mean of 0.63.  Effect sizes for 
anxiety had a lower bound for outliers of –0.91, and an upper bound of 1.89.  One effect 
size fell outside this range, d =2.67.  A homogeneity analysis was conducted and the 
results indicated a heterogeneous distribution (χ2 (14) = 166.06, p <0.001).  The null 
hypothesis for homogeneity was rejected suggesting that it cannot be assumed that the 
data contains only subject level variability, but also some study level variability, and 
indicating the use of a random effects model.   
The mean effect size for the sample of studies under the random effects model 
was .66 (SE = .23) and was statistically significant (z =2.92, p = 0.035).  The 95% 
confidence interval around the mean effect size (0.22 < µ < 1.10) did not include zero and 
reveals the relevant precision of the estimate of the mean effect size.  The variance 
component for the random effects analysis is 0.69 indicating that approximately 69% of 
the variance is not accounted for by sampling error.  
Several analyses were conducted to test the ability of several categorical and 
continuous variables to explain the excess effect size variability.  Results of these 
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analyses are summarized in Tables 3 and 4.  For anxiety, scientific quality, number of 
CBT components, number of weeks, and attrition rates did not significantly contribute to 
the variability in anxiety.  Number of sessions did account for 29% of the variance 
(R2=0.29, p = 0.02) in effect sizes for anxiety.  For the random model the value of the 
variance component for type of CBT treatment was statistically significant Q (1) = 5.94, 
p = 0.015.  Studies using group CBT (n= 13) had a mean d  = 0.44 (SE = 0.19) and a 95% 
confidence interval 0.07 to 0.82, which was significantly different from multidisciplinary 
CBT (n= 4) having a mean d = 1.47 (SE = 0.37) and a 95% confidence interval of .74 to 
2.20.  
Psychological distress 
After aggregation there were twelve effect sizes for the dependent measure 
psychological distress which ranged from d = -0.10 to d = 2.67 with a mean of .81.  
Effect sizes for psychological symptoms had a lower bound for outliers of –0.89 and an 
upper bound of 2.26.  One effect size fell outside this range, d =2.67.  A homogeneity 
analysis was conducted and the results indicated a heterogeneous distribution (χ2 
(11)=57.24, p <0.001).  The null hypothesis for homogeneity was rejected suggesting that 
it cannot be assumed that the data contains only subject level variability, but also some 
study level variability, and indicating the use of a random effects model.   
The mean effect size for the sample of studies under the random effects model 
was 0.76 (SE = 0.20) and was statistically significant (z =3.84, p = 0.0001).  The 95% 
confidence interval around the mean effect size (0.37 < µ < 1.14) did not include zero and 
reveals the relevant precision of the estimate of the mean effect size.  The variance 
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component for the random effects analysis is 0.35 indicating that approximately 35% of 
the variance is not accounted for by sampling error.  
Several analyses were conducted to test the ability of several categorical and 
continuous variables to explain the excess effect size variability.  Results of these 
analyses are summarized in Tables 3 and 4.  For psychological distress, scientific quality, 
number of CBT components, and attrition rates did not significantly contribute to the 
variability in depression.  Number of sessions did account for 38% of the variance 
(R2=0.38, p = 0.01) in effect sizes for psychological distress.  Number of weeks of 
treatment did account for 38% of the variance (R2=0.38, p = 0.01) in effect sizes for 
psychological distress.  For the random model the value of the variance component for 
type of CBT treatment was statistically significant Q (2) = 5.47, p = 0.04.  Studies using 
individual CBT (n= 2) had a mean d  = 1.75 (SE = 0.52) and a 95% confidence interval of 
0.73 to 2.76, which was not significantly different from multidisciplinary CBT (n= 2) 
having a mean d = 1.03 (SE = 0.43) and a 95% confidence interval of 0.19 to 1.88; 
however, group CBT treatment (n= 7) was significantly different from both having a 
mean of d = 0.49 (SE = 0.22) and a 95% confidence interval of .06 to .93.  
 
Table 3.  Variance components of the regression analysis by dependent variable 
Dependent Variable Regression Variables 
 
Attrition (R2) 
Number of 
Session (R2) Weeks (R2) 
Number of CBT 
Components (R2) 
Functional Status .07 .30* .01 .04 
Pain .001 .27* .01 .01 
Depression .04 .21* .02 .10 
Anxiety .02 .29* .001 .07 
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Psychological Distress .03 .38* .36* .19 
* p < .05 
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Table 4.  ANOVA comparisons for moderator’s variables on the dependent variables 
 Moderator 
Variable 
n  (Effect 
sizes) 
Mean 95% Confidence 
Interval 
 
Treatment Modality 
 Functional Status Individual 3 0.74 -0.44 – 1.91  
  Group 18 0.47 0.10 – 0.84  
  Multidisciplinary 5 1.34 0.59 – 2.09  
 Pain Individual 4 0.60 -0.35 – 1.56  
  Group 25 0.67* 0.36 – 0.98  
  Multidisciplinary 5 2.01* 1.27 – 2.74  
 Depression Group 16 0.52* 0.23 – 0.81  
  Multidisciplinary 4 1.46* 0.82 – 2.09  
 Anxiety Group 23 0.44* 0.06 – 0.82  
  Multidisciplinary 4 1.47* 0.74 – 2.20  
 Psychological Individual 3 1.75* 0.73 – 2.76  
  Group 9 0.49* 0.06 – 0.93  
  Multidisciplinary 3 1.03* 0.19 – 1.88  
Scientific Quality      
 Functional Status High 15 0.49 0.06 – 0.92  
  Low 9 0.96 0.38 – 1.53  
 Pain High 20 0.70 0.31 – 1.09  
  Medium 4 0.56 -0.40 – 1.53  
  Low 10 1.26 0.70 – 1.83  
 Depression High 11 0.52 0.12 – 0.92  
  Medium 3 0.41 -0.47 – 1.28  
  Low 7 1.06 0.54 – 1.57  
 Anxiety High 8 0.37 -0.15 – 0.88  
  Medium 4 0.39 -0.40 – 1.18  
  Low 6 1.23 0.62 – 1.84  
 Psychological High 8 0.78 0.16 – 1.39  
  Low 5 0.82 0.003 – 1.65  
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* p < .05, CBT = Cognitive Behavioral Therapy 
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DISCUSSION 
This meta-analysis reviews the evidence in support of the use of CBT for 
individuals with fibromyalgia.  Individuals with fibromyalgia experience many symptoms 
including pain, fatigue, decline in overall functioning, sleep problems, as well as, 
psychological sequelae such as depression, anxiety and general distress.  This analysis 
found positive results for the application of CBT to individuals experiencing the 
symptoms of fibromyalgia.  CBT can be helpful in reducing pain, depression, anxiety and 
general distress.  Furthermore, CBT can be effective in increasing overall functioning in 
these individuals; this includes reduction in doctor’s visits, improvements in physical 
functioning and overall improvements in quality of life.  
Specifically, this meta-analysis found a moderate effect size for the improvement 
of functional status as a result of a CBT treatment.  Functional status includes various 
constructs that are all related to the physical, social, and occupational functioning of a 
person as it relates to how they can manage their life and their pain.  Furthermore, CBT 
for fibromyalgia was found to reduce pain symptoms in this study.  The effect size was 
determined to be large, which was unexpected given that both reviews of CBT for 
fibromyalgia were skeptical of any effect CBT might have on pain (Bennett & Nelson, 
2006; van Koulil et al., 2008).  This review offers new evidence that CBT may reduce 
pain in people with fibromyalgia.  However, these results must be interpreted cautiously 
as the 95% confidence interval was wide (see Table 5).  
The psychological variables examined were found to have medium average effect 
sizes.  In particular, the average effect size for depression was found to be medium.  One 
hypothesis for this finding could be that CBT for individuals with fibromyalgia has an 
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effect on the somatic symptoms of depression, which may overlap with the experience of 
chronic widespread pain, but this would require further investigation.  The average effect 
size for both anxiety and psychological distress were medium, confirming that CBT can 
be at least somewhat effective in reducing psychological distress and anxiety in 
individuals with fibromyalgia.  All average effect sizes are summarized in the table below 
(see Table 5).  
 
Table 5.  Average effect sizes across dependent variables 
Dependent Variable Average Effect Size 95% Confidence Interval 
Functional Status 0.65 0.30 – 0.99 
Pain 0.85 0.53 – 1.17 
Depression 0.69 0.34 – 1.04 
Anxiety 0.66 0.22 – 1.10 
Psychological Distress 0.76 0.37 – 1.14 
 
 
Effect sizes should be considered in a larger scientific context, but for behavior 
sciences that one could use the general guidelines of “small”, medium” and “large” effect 
sizes as >0.20, =0.50, and >0.80 respectively (Cohen, 1977, 1988). This scientific 
community typically recognizes these guidelines to give meaning to effect size statistics.  
However, there is another way to examine the interpretation of effect sizes.  More 
recently investigators have uses a “Fail-Safe N” to examine how many studies with an 
effect size of zero would be necessary to negate the results of the study (Rosenthal, 
1979). This method attempts to counteract the “file-drawer problem” where studies with 
null effect sizes are not published, creating a bias.  In this study, a conservative effect size 
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of 0.2 was selected because it would likely represent a non-significant effect size and 
would be considered “small.”  For this meta-analysis 51 studies with an effect size of 
zero would be required to reduce the effect size of functional status to d=0.20.  One 
hundred studies with an effect size of zero would be required to reduce the effect size of 
pain to d=0.20.  Forty-four studies with an effect size of zero would be required to reduce 
the effect size of depression to d=0.20.  Thirty-four studies with an effect size of zero 
would be required to reduce the effect size of anxiety to d=0.20.  Thirty-three studies 
with an effect size of zero would be required to reduce the effect size of psychological 
distress to d=0.20.  Thus, the results from this study appear to be robust. 
The studies included in the analysis included a wide variety of study designs 
including randomized trials and pilot studies that did not include control group.  This was 
done in an attempt to gather as much evidence as possible to determine the degree of 
various symptoms of fibromyalgia.  Thus, all studies examining CBT in individuals with 
fibromyalgia were included regardless of scientific quality.  A variable was created in an 
attempt to measure scientific quality. However, 60% of the studies were coded as high in 
scientific quality because they included a control group and the subjects were randomly 
assigned.  Twelve percent of studies were coded as medium scientific quality, indicating 
that there was a control group, but groups were not randomly assigned.  Thus, 28% of 
studies were coded in the “low” scientific quality, indicating that there were no 
comparison groups in the study.  When ANOVAs were conducted to determine if there 
were significant differences in effect sizes between high, medium, and low scientific 
quality none of the analyses were significant (see Table 4).  While mean effect sizes 
reported in Table 4 for scientific quality do appear to demonstrate a “trend” in that 
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studies coded as “low” in scientific quality have higher mean effect sizes in general, there 
was considerable variability in effect sizes across conditions.  
Secondary analyses were performed on the data to determine if other aspects of 
the studies were contributing to the average effect sizes.  Scientific quality of the studies, 
attrition rates, number of CBT components and number of weeks of treatment did not 
significantly contribute to the average effect sizes across dependent variables.  However, 
the number of sessions indicated for treatment did account for a significant amount of the 
variance across average effect sizes across dependent variables.  In particular, as the 
number of sessions increased the average effect sizes increased. 
Furthermore, the type of CBT treatment, whether it be individual therapy, group 
therapy, or multidisciplinary therapy significantly impacted average effect sizes.  In 
general, group therapy effect sizes were lower than both individual and multidisciplinary 
therapy.  This may indicate that CBT group therapy for individuals may be less effective 
that individual treatment or multidisciplinary treatment.  This is consistent with the 
results from the review of non-pharmacological treatments for fibromyalgia, which noted 
that CBT is typically more effective in combination than on its own (van Koulil et al., 
2007).  However, the majority of the studies included in the meta-analysis were 
measuring the effectiveness of group treatment (n=25), while a minority of studies 
included individual therapy (n=4) and multidisciplinary treatment (n=5).  
In particular, one of the studies (Kroese et al., 2009) used a multidisciplinary 
therapy that contained eight upper bound outliers.  In spite of this, the study was left in 
because it met all inclusion and exclusion criteria.  All statistical analyses were run 
excluding this study.  In this case, the average effect sizes across the dependent variables 
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were lower when the study was removed from the data.  Furthermore, the ANOVA 
conducted to determine if types of CBT treatments contribute to the average effect sizes 
was non-significant across dependent variables when this study was removed.  Thus, this 
study may have arbitrarily inflated effect sizes in the multidisciplinary group.  
The results of this meta-analysis are not in direct conflict with conclusions drawn 
from recent literature reviews of CBT for fibromyalgia; however, the data presented 
above does serve to provide further evidence and clarification to reviews of the literature.  
Previous research has reviewed the use of psychological therapies for fibromyalgia.  
Beginning in 1999, Rossy et al. reviewed pharmacological and nonpharmacological 
therapies for fibromyalgia and determined that psychological therapies had medium 
positive effects for variables of physical status, self-report of fibromyalgia symptoms, 
psychological status and daily functioning (Rossy et al., 1999). In 2002, Sims and Adams 
conducted the first review of evidence for nonpharmacological therapies for 
fibromyalgia, at this point they determined that the available literature was inadequate to 
come to any conclusions about effectiveness of psychotherapy for individuals with 
fibromyalgia.  At this point, they recommended that researchers use consistent measures 
for outcomes in their studies.  Specifically they recommended the Fibromyalgia Impact 
Questionnaire (FIQ) in the current quantitative review, 16 out of 32 groups used the FIQ 
as an outcome measure (Burckhardt, Clark, & Bennett, 1991).  Goldenberg (2004) 
conducted a systematic review of all therapies for fibromyalgia and suggests that low 
dose tri-cyclic antidepressants, exercise, CBT and patient education show preliminary 
effectiveness for the symptoms of fibromyalgia (Goldenberg, Burckhardt, & Crofford, 
2004).  In 2006, Bennett and Nelson specifically reviewed research using CBT as the 
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whole or part of the treatment for fibromyalgia.  They determined that CBT can be 
effective making short term changes in pain-related behavior, coping strategies, and 
overall physical function; however, they questioned whether CBT could be effective in 
reducing pain in this population.  Van Koulil et al. (2007) added that outcomes for non-
pharmacological therapies are promising in the short term; however, outcomes may 
disappear long term.  Two recent quantitative reviews (Glombiewski et al., 2010; Thieme 
& Gracely, 2009) have examined psychological interventions for fibromyalgia and found 
promising effect for pain reduction and in particular found improvement in functional 
status, depression, and catastrophizing.  Furthermore, Glombiewski et al. (2010) found 
that psychological interventions can be effective over the long term.  
In light of these findings, this study specifically examines the role of CBT in 
fibromyalgia, which appears to have the most evidence compared with other non-
pharmacological interventions.  Furthermore, the effect sizes found in this meta-analysis 
are somewhat higher than those reported in previous quantitative reviews (Glombiewski 
et al., 2010). The current study provides evidence in support of the effectiveness of CBT 
for symptoms of anxiety in individuals with fibromyalgia.  
Limitations and future directions 
The primary limitation of the evidence presented above is related to the inclusion 
criteria for this study.  The analysis was completed on data from pre- and post- CBT 
intervention as opposed to a comparison of difference scores between control and 
treatment groups; thus, participants act as their own controls, not to a control group that 
did not receive treatment.  The limitation of this method used in this study is that the 
effect sizes listed can only represent expected change of participant scores from before to 
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after treatment without controlling for other variables.  This represents a fundamental 
difference from most meta-analyses performed in the field of chronic pain.  Furthermore, 
it represents a difficulty in interpretation of the effect sizes obtained from this study, 
since prior meta-analyses in this field have not examined pre-post differences in their 
quantitative reviews, there is little with which to compare the results of this study. 
Most studies were done with middle age women of unknown ethnicity and socio-
economic status.  Attempts were made to document ethnicity and socioeconomic status 
for analysis; however, only a few of the studies documented these characteristics in their 
demographics.  Thus, the demographics of the population to which these results apply are 
still unknown. 
Internal validity of this study is in question due to the wide range of measures 
used to capture the dependent variables.  This reduces confidence in the constructs 
themselves if they contain potentially different constructs within them.  In meta-analysis, 
this represents the central controversy of apples vs. oranges.  In particular, this meta-
analysis used studies examining treatments which could all be classified as CBT, but 
which may include other treatment modalities such as medications or exercise in 
addition.  This meta-analysis included a wide array of outcome measures that were 
assimilated into five distinct outcome measures.  In an ideal world, researchers would 
have used consistent outcome measures to examine their dependent variables of interest.  
That said, many researchers have adopted common outcome measures such as the 
Fibromyalgia Impact Questionnaire (Burckhardt et al., 1991), as was recommended by 
(Sim & Adams, 2002). In this study, 16 of the 32 groups used the FIQ to measure 
outcomes. For example, it is possible to say that CBT for Fibromyalgia can reduce pain 
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symptoms, but we cannot say specifically that relaxation combined with cognitive 
restructuring will reduce Visual Analog Scale (VAS) pain scores. 
While some attempt was made to measure scientific quality of these studies, by 
using a rating scale which differentiated between studies that were “high” (used a control 
group and assignment), “medium” (used a control group),  “small” (did not have a control 
group), this effort was based on the assumption that utilized these designs would have 
been respectively rigorous in their implementation of other scientific controls.  However, 
this assumption is questionable, and furthermore (as mentioned above), this meta-analysis 
did not examine the results of control groups, this study only examined the pre- and post 
outcomes of treatment groups.  Therefore, the attempts made in this study to measure 
scientific quality are lacking in scientific quality. 
Finally, it is not known how the effects of CBT change/remain over time.  This 
study did not examine follow up data.  While it was available for some of the studies in 
this meta-analysis, it was available for fewer than half of the studies and was not 
collected.  
Improvements to this study to increase its scientific quality and relevancy would 
be to examine studies which provided follow up data to examine how effects change or 
remain the same over time.  In a recent quantitative review, Glombiewski et al. (2010) 
reported that an increase in effect size was noted in studies that examined pain intensity 
over and average of 7.4 months; thus, long-term gains were maintained and even 
improved upon over time.  Furthermore, the internal validity of this study could be 
improved by including only randomized control trials without other interventions 
included.  For example, studies varied widely in their inclusion of medications in addition 
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to CBT in the treatment description, and some studies also included various forms of 
exercise.  In order to truly examine the effect of CBT in individuals with fibromyalgia it 
would be necessary to only use studies that only examined CBT and compared it to a 
wait-list control, treatment as usual, or pharmacological approaches.  
Additionally, one recommendation for future meta-analyses would be to include a 
standardized measure of scientific quality, such as the Jadad scale, typically used for 
randomized control trials (Jadad et al., 1996).  Most scales rely heavily on whether 
treatments are blinded and how subjects are assigned to group; however, this would not 
be an effective way to capture scientific quality in this particular type of meta-analysis 
because they are based on the conditions applied to the control group and this meta-
analysis only regards the treatment group.  Rather, it would be important to capture other 
aspects such as sample characteristics (selection and homogeneity), attrition, threats to 
internal validity, and the reliability and validity of the outcome measures, which would 
likely capture scientific quality of the studies. 
Conclusions/Summary 
From the results of this meta-analysis, it can be summarized two moderators 
where found to impact effects sizes.  The first, treatment duration was found to impact 
effect size, accounting for approximately one third of the variance in effect sizes notably 
across treatment outcomes.  This finding has been replicated in other reviews of 
psychological treatments for fibromyalgia, which implies that individuals with 
fibromyalgia respond best to interventions with multiple sessions (Glombiewski et al., 
2010; Thieme & Gracely, 2009; van Koulil et al., 2007).  The other moderator that 
emerged from this analysis was that CBT that is situated within a multidisciplinary 
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program may be more effective that when provided individually or in a group setting.  
However, more evidence is necessary to confirm this finding because it is based on only 
five studies. 
The field of psychological treatments for individuals with fibromyalgia has made 
significant gains in providing evidence for the effectiveness of these therapies, 
specifically CBT.  Thirty-two groups were reviewed for this meta-analysis, which is a 
significant increase from the first review of this literature by Rossy et al. (1999), which 
examined evidence from 16 groups.  However, considerable gaps still remain in the 
literature.  First, researchers should continue to use commonly used, reliable and valid 
outcome measures for monitoring outcomes such as pain, functional status, depression, 
anxiety, fatigue and sleep problems.  They should also continue to monitor outcomes 
over the long term and aim to develop interventions, which provide lasting effects.  
Furthermore, the research base would be strengthened by conducting more randomized 
blinded controlled studies to measure the effects of CBT and CBT in a multidisciplinary 
program, and research should be compared with exercise, and pharmacological therapies.  
Finally, related to recent research suggesting that different therapies may be more 
effective for certain individuals, in may be useful to examine treatment outcomes based 
on patient profiles such as those with adequate social support, those with significant 
emotional comorbidity, or those with high levels of pain. 
In summary, while there are some limitations to this qualitative review, the 
evidence supporting the use of CBT to improve functioning, decrease pain, depression, 
anxiety and psychological distress is strong.  
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APPENDIX A 
Coding Manual 
Study identification number (ID):  
Bibliographic reference:  
Publication year (YR): 
 
Sample descriptors 
Mean age: specify the approximate or exact mean age at the beginning of the intervention 
(if cannot be determined code: 999) (AGE) 
Predominant sex of sample: exact proportion of women in the sample (SEX) 
999 not reported 
Average duration of fibromyalgia in the sample in years (DURATION) (if cannot be 
determined code: 999) 
Is the sample taking medications? (MEDS) 
1 Yes- not controlled 
2 Yes- controlled/documented 
3 No 
99 Unable to determine 
 
Research design descriptors 
Type of therapy (UNIT) 
1 Individual cbt 
2 Group cbt 
3 Multidisciplinary treatment 
999 Cannot be determined 
Scientific rigor (SCIR): 
1 Random assignment + pre test differences (high) 
2 Control group of any kind (medium) 
3 No control group (low) 
999 Cannot be determined 
CBT Treatment group size (Start) (TXSIZE1) (999 Cannot tell) 
CBT Treatment group size (End)  (TXSIZE2) (999 Cannot tell)  
Attrition (TXSIZE2/TXSIZE1x100) 
 
Nature of the treatment descriptors 
What are the components of CBT included in the treatment? (1-yes / 0-no) 
Exposure, behavior mod (CBT_expbm) 
Stress management (CBT_sm) 
Problem solving (CBT_ps) 
Relaxation training (CBT_rt) 
Homework (CBT_hw) 
Education (CBT_edu) 
Support person involvement (CBT_sup) 
Biofeedback (CBT_bio) 
Self monitoring/goals (CBT_goal) 
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Cognitive restructuring (CBT_cr) 
Self-management of chronic pain (CBT_smcp) 
Exercise (CBT_ex) 
Sleep hygiene (CBT_sh) 
Assertiveness training/ social skills training (CBT_astss) 
Pleasant activity scheduling (CBT_pas) 
Relapse prevention (CBT_rp) 
Duration of the treatment in weeks  
From pre test to post test (missing =999) (WEEKS) 
Number of treatment sessions (NO SESSION) 
Duration of sessions (minutes) (SESSDUR) 
Time to follow up in months (FUMONTHS1) 
Time to follow up in months (FUMONTHS2) 
Time to follow up in months (FUMONTHS3)  
Time to follow up in months (FUMONTHS4)  
 
Effect size level coding manual 
Effect size number (ESNUMBER) 
Dependent measure descriptors: 
Name of scale: (SCALNAME) 
Type of scale: (SCALTYPE) 
1 Self-report 
2 Self-rated pain index - composite 
3 Observers rating 
4 Clinician ratings 
5 Objective tests (physical) 
Category of outcome construct/ specific measure: (CATOUT / CATSPEC) 
1 Functional 
1 Activity, MPI – activity 
2 QWB 
3 FIQ – physical  
4 SF 36 – physical  
5 SF 36 – functional, quality of life – EQ-D5 
6 MPI – control/mastery (incl. csq) 
7 FIQ – feeing good/wellbeing  
8 Exercise (work capacity, functional capacity measurements, objective tests)  
9 Visits to doctor  
10 Functional disability – HAQ 
11 VAS well being 
12 IRGL disability 
 2 Pain 
1 Intensity/severity (MPI/Q- Intensity and severity) 
2 Self/Observer report of pain behaviors (OBS, Tubingen, PBCL, UAB) 
3 VAS Pain score 
4 Index/composite pain score 
5 Myalgia score / Dolorimeter / Tender points 
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6 Interference (MPI) 
7 FIQ – total  
8 BPI 
9 MPQ subscales (incl. - affective distress) 
10 HAQ – symptoms soma/pain 
11 FIQ – Pain  
12 IRGL Pain 
13 VAS Pain during exercise 
3 Depression 
1 BDI 
2 VAS – Depression  
3 CES-D 
5 FIQ – feeling good  
6 FIQ – depression  
7 CDI 
11 IRGL Negative Mood 
12 SF36 MH composite score 
4 Anxiety 
1 Fear (FS-III-R) 
2 MOCI – Obsessive Compulsive 
3 BAI 
4 FIQ – anxiety  
5 STAI – S/T 
6 PES – worry  
7 VAS – anxiety 
8 IRGL anxiety 
5 psychosocial distress 
4 SCLR-90/BSI – GSI   
8 POMS 
9 MPI – affective  
10 PES/emotionality 
 
Effect size data 
Page number where the effect size was found (ESPAGE) 
TX group size – total N at Posttest, i.e. useable data points (SSTX) 
Treatment group mean pre-intervention (TX_PreMN) 
Treatment group standard deviation pre-intervention (TX_PreSD) 
Treatment group mean post-intervention (TX_PostMN) 
Treatment group standard deviation post-intervention (TX_PostSD) 
Effect size (ES) 
Raw difference shows improvement (RAW) 
1 Yes 
2 No- Decline 
3 No change (or statistically insignificant) 
999 Cannot tell  
